Company: GLPG
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001558370-25-003806
Chunk: 402

Company: GALAPAGOS NV
Filing Date: 2025-03-27
Form: 20-F
Item: Item 16I
Chunk 402
---
31, 2022 of €5.1million of filgotinib development cost sharing receivables and €2.6million royalties receivables.
(2) Upfront and milestone payments recognized in accordance with the percentage of completion of the underlying obligation.
(3) Shown as decrease of research and development expenditure.
(4) Net amount shown as an (increase)/decrease of research and development expenditure.
(5) Profit/cost share mechanism came to an end beginning of 2022.
As at December 31, 2023 we hadtwooutstanding performance obligations under IFRS 15 towards Gilead, being the performance obligation related to our drug discovery platform and the performance obligation relating to filgotinib before its transfer to Alfasigma on January 31, 2024, following the closing of the transaction for the transfer of the Jyseleca® business. The remaining deferred income for the performance obligation relating to filgotinib, amounting to €26.3million at December 31, 2023, was recognized in revenue in 2024. The outstanding deferred income balance at December 31, 2024 for the drug discovery platform amounted to €1.1billion.
A detailed explanation of our transactions with Gilead in 2022, 2023 and 2024 can be found in the section of this annual report titled “ Item 4 - Information on the Company”, subsection “ Collaborations”.
There are no other shareholders or other entities who, solely or jointly, control us or exercise significant influence over us.

F-65

Table of Contents

Relationship and transactions with subsidiaries
Please see note 34 for an overview of the consolidated companies of the group, which are all wholly-owned subsidiaries of Galapagos NV.
Relationship and transactions with key management personnel
Our key management personnel consists of the members of the Executive Committee and members of the Board of Directors. All amounts mentioned in this section are based on expenses recognized in the financial statements for the relevant financial year.
Remuneration of key management personnel
On December 31, 2024, our Executive Committee hadfourmembers: Stoffels IMC BV (permanently represented by Dr. Paul Stoffels), Mr. Thad Huston, Ms. Valeria Cnossen and Ms. Annelies Missotten. They provide their services to us on a full-time basis.
On December 31, 2024, our Board of Directors consisted ofn